Researchers identify key molecular alterations from endurance exercise that could combat chronic diseases

FHS
May 3, 2024
9:41 am

A whole-organism molecular map of the temporal effects of endurance training in rats.

Relmada’s rapid-acting NMDA depression drug expected to fail second Phase 3

Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price. …

December 5, 2024

IL-31 Drug for Itchy Nodular Skin Disease Gets Thumbs Up From FDA

The FDA approved the interleukin (IL)-31 monoclonal antibody nemolizumab (Nemluvio) for treating prurigo nodularis, drugmaker Galderma announced on Tuesday. The approval stipulates use in adults

August 14, 2024

Dietary interventions improve mitochondrial function and reduce inflammation in obesity

Study demonstrates that dietary interventions such as calorie restriction, intermittent fasting, and ketogenic diet improve mitochondrial function in monocytes and reduce inflammation in obesity by

July 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.